Theralase Technologies (TLT) Stock Price, News & Analysis

Company Overview

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.

Key Stats

• Today's Range: C$0.28 to C$0.29
• 50-Day Range: C$0.25 to C$0.31
• 52-Week Range: C$0.14 to C$0.38
• Volume: 43,500 shs
• Average Volume: 101,698 shs
• Market Capitalization: C$68.18 million
• P/E Ratio: N/A
• Dividend Yield: 1,035.71%
• Price Target: N/A
• Consensus Rating: N/A

TLT Stock Analysis - Frequently Asked Questions

How have TLT shares performed this year?

Theralase Technologies' stock was trading at C$0.27 at the beginning of the year. Since then, TLT shares have increased by 5.7% and is now trading at C$0.28.
View the best growth stocks for 2025 here.

How do I buy shares of Theralase Technologies?

Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Theralase Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: CVE:TLT
• CUSIP: N/A
• CIK: N/A
• Web: theralase.com
• Phone: +1-416-6995273
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-4,492,945.96
• Net Margins: -438.78%
• Pretax Margin: N/A
• Return on Equity: -225.69%
• Return on Assets: -81.88%

Debt

• Debt-to-Equity Ratio: 14.85
• Current Ratio: 1.91
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: C$1.02 million
• Price / Sales: 66.59
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 30.45
• Book Value: C$0.01 per share
• Price / Book: 30.71

Miscellaneous

• Outstanding Shares: 243,507,931
• Free Float: N/A
• Market Cap: C$68.18 million
• Optionable: Not Optionable
• Beta: 1.36